Convalescent plasma therapy prevents acute respiratory distress syndrome in patients with SARS-CoV-2 virus disease

Consuelo Macías Abraham, Delia Esther Porto González, Ariel Legrá Ayala, Mariela Forrellat Barrios, Rosa María Lam Díaz, Damisela Cordoví Rodríguez, Lillebit Ortega León, Laura Ballester Planes, Kalina García Domínguez, Zuleidi González Maldonado, Zunilda FrómetaTolón, Milaidys Rodríguez Hernández, Judith Rodríguez Alonso, Tania Morales Quiñones, Thalia Valdivia Valido, Irinia Valdivia Alvarez, Aurora Delahanty Fernández, Darien Ortega León, Ariel Palenzuela Díaz, Vivian Kourí Cardellá

Texto completo:



BACKGROUND: SARS-CoV-2 disease 2019 is a pandemic with no specific therapeutic agents and substantial mortality. The success of convalescent plasma therapy is based on the transfused plasma had high concentrations of anti-SARS-CoV-2 antibodies, and on the safe preparation of serum to eliminate potential risk factors, such as the transmission of viruses via transfusion.
STUDY DESIGN AND METHODS: Five patients laboratory confirmed COVID-19, diagnosed using reverse transcriptase–polymerase chain reaction (RT-PCR) classified like of care and seriously non-ventilated patients with moderate hypoxemia were received 300 mL convalescent plasma treatment. Each donation was tested for antibody titersIgG class anti-SARS-CoV-2 by UMELISA. The transfused plasma units had an average antibody titer of 836.00 ± 617.155. The time interval between the onset of symptoms and transfusion was 9 days (7.20± 3). Before and after each transfusion, clinical and laboratory parameters were evaluated.
RESULTS:At 24-hour after the plasma transfusion, oxygen partial pressure increased from medium value of 70.4 to 101.6 mm Hg, C-reactive protein and lactate dehydrogenase enzyme values decreased in 3 of 5 patients; however, the ferritin values increased in all the patients. Post-transfusion hospital discharge time was from 48 hours to 12 days and the SARS-CoV-2 PCR was negative between 3 and 5 days. No adverse transfusion reactions were reported.
CONCLUSION:This report emphasis about the efficacy and security of convalescent plasma transfusion to care and seriously non-ventilated patients infected like a preventive therapy for severe respiratory distress for SARS-CoV-2 virus disease.

Palabras clave

convalescent plasma, SARS-CoV-2 virus, COVID-19, coronavirus, ARDS

Copyright (c) 2020 Licencia Creative Commons Reconocimiento-NoComercial-Compartir Igual 4.0 Unported.

Licencia de Creative Commons
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional.